Takeda Canada Wins Purchase Deal for Adynovate for Hemophilia A

Yedida Y Bogachkov PhD avatar

by Yedida Y Bogachkov PhD |

Share this article:

Share article via email
Adynovate | Hemophilia News Today | illustration of a handshake

Canadian Blood Services (CBS) has awarded a three-year tender — an exclusive bulk purchase agreement aiming to minimize medication cost — to Takeda Canada for the purchase of Adynovate, an injectable replacement therapy for the prevention and treatment of bleeding episodes in people with hemophilia A.

This is the second consecutive tender that Takeda has won from CBS for Adynovate, and it includes two one-year options.

“Being able to continue to provide Canadian hemophilia patients with this important treatment option is a tremendous source of pride for Takeda,” Rute Fernandes, general manager at Takeda Canada, said in a press release.

Recommended Reading
AMT-061, Phase 3 trial data

Adynovate Prophylaxis Continues to Show Promise in Severe Hemophilia A, Trials’ Data Show

Adynovate is based off of Advate, an artificially made version of factor VIII (FVIII), the blood-clotting protein that is missing or defective in hemophilia A patients. As opposed to Advate, Adynovate contains a lab-made version of FVIII that has been attached to the nontoxic molecule polyethylene glycol (PEG). This allows Adynovate to remain in the bloodstream for a longer period of time than its predecessor.

Adynovate is specifically meant to control, prevent, and lower the frequency of bleeding episodes, as well as manage bleeds associated with surgeries, in children and adults with hemophilia A. In Europe, the medication is sold under the brand name Adynovi.

As part of the tendering process, Takeda presented a model that transitioned away from price-based criteria toward a more value-based criteria, in response to CBS’s own value-based criteria. This transition indicates a path toward a more sustainable model for procuring goods and service and an overall more integrated, holistic approach to supporting those with hemophilia A, the company stated.

“Adopting a holistic approach that incorporates real world evidence, delivers personalized care, and support services that address the needs of patients beyond their treatment, underscores Takeda’s commitment to patients and providing value to the healthcare system,” Fernandes said.

“We look forward to continuing our relationship with Canadian Blood Services, and through it, being able to extend the benefits of ADYNOVATE as well as the support services we are committed to making available for patients,” she added.